96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

27 trials found

diseases per page:

Showing 1 to 10 of 27 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000043165	2021/02/01	31/01/2021	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilar CT- ...	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilar CT- ...	Crohn's disease, Ulcerative colitis, IBDU	witching from originator infliximab to infliximab biosimilar CT-P13	Fukuoka University Chikushi Hospital	NULL	Pending	Not applicable	Not applicable	Male and Female	220	Not selected	Japan
2	JPRN-jRCT2031200117	01/09/2020	11/09/2020	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Crohns Disease	Biological: CT-P13 SC (Infliximab) Other: Placebo SC	Ishida Tetsuya	Celltrion	Not Recruiting	>= 18age old	<= 75age old	Both	600	Phase 3	US;Latvia;Czech Republic;France;Poland;Germany;Greece;Hungary;Spain;Austria;Bulgaria;Croatia;Japan
3	EUCTR2019-001087-30-RO (EUCTR)	15/04/2020	21/03/2022	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product Code: CT-P13 INN or P ...	Celltrion, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Chile;I ...
4	EUCTR2019-001087-30-AT (EUCTR)	28/11/2019	12/09/2019	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product Code: CT-P13 INN or P ...	Celltrion, Inc	NULL	Not Recruiting			Female: yes Male: yes	600	Phase 3	United States;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Ireland;Chile;Israel;Russian Federation;I ...
5	EUCTR2019-001087-30-HR (EUCTR)	11/11/2019	17/01/2020	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product Code: CT-P13 INN or P ...	Celltrion, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Ireland;Russian Federation;Chile;Israel;I ...
6	EUCTR2019-001087-30-DE (EUCTR)	31/10/2019	01/07/2019	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Trade Name: Remsima Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product C ...	Celltrion, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Italy;Ind ...
7	EUCTR2019-001087-30-BG (EUCTR)	30/10/2019	24/10/2019	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Trade Name: Remsima Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product C ...	Celltrion, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Portugal;Serbia;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
8	NCT03945019 (ClinicalTrials.gov)	October 28, 2019	8/5/2019	CT-P13(Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn' ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Crohn's Disease	Biological: CT-P13 SC (Infliximab);Other: Placebo SC	Celltrion	NULL	Active, not recruiting	18 Years	75 Years	All	397	Phase 3	Poland;United States
9	EUCTR2019-001087-30-IT (EUCTR)	10/09/2019	17/01/2022	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn's Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Trade Name: Inflectra Product Name: / Product Code: [CT-P13] INN or Proposed INN: INFLIXIMAB Trade Name: ...	CELLTRION INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	United States;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Ind ...
10	EUCTR2019-001087-30-PL (EUCTR)	09/09/2019	24/06/2019	Evaluating efficacy and safety of subcutaneous CT-P13(CT-P13SC) as maintenance therapy in patients w ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...	Trade Name: Remsima Product Code: CT-P13 INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra Product C ...	Celltrion, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Serbia;Portugal;United States;Belarus;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...

First Previous1 2 3Next Last